{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T07:24:26Z","timestamp":1768548266760,"version":"3.49.0"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,3,17]],"date-time":"2018-03-17T00:00:00Z","timestamp":1521244800000},"content-version":"am","delay-in-days":350,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["31003A-159454"],"award-info":[{"award-number":["31003A-159454"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["P26782"],"award-info":[{"award-number":["P26782"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swiss Center for Applied Human Toxicology (SCAHT)"},{"name":"Swiss Federal Office of Public Health (FOPH)"},{"name":"Novartis Research Foundation"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.bcp.2017.01.010","type":"journal-article","created":{"date-parts":[[2017,1,25]],"date-time":"2017-01-25T14:46:16Z","timestamp":1485355576000},"page":"93-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Inhibition of 11\u03b2-hydroxysteroid dehydrogenase 2 by the fungicides itraconazole and posaconazole"],"prefix":"10.1016","volume":"130","author":[{"given":"Katharina R.","family":"Beck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murielle","family":"B\u00e4chler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Vuorinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Akram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Griesser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika","family":"Temml","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Klusonova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Odermatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bcp.2017.01.010_b0005","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.mce.2011.07.020","article-title":"Tissue-specific modulation of mineralocorticoid receptor function by 11\u03b2-hydroxysteroid dehydrogenases: an overview","volume":"350","author":"Odermatt","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bcp.2017.01.010_b0010","first-page":"1178","article-title":"The role of 11\u03b2-hydroxysteroid dehydrogenase type 2 in human hypertension","volume":"2010","author":"Ferrari","year":"1802","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.bcp.2017.01.010_b0015","first-page":"135","article-title":"11\u03b2-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess","volume":"18","author":"White","year":"1997","journal-title":"Endocr. Rev."},{"issue":"5","key":"10.1016\/j.bcp.2017.01.010_b0020","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1210\/jcem-44-5-924","article-title":"Evidence for an unidentified steroid in a child with apparent mineralocorticoid hypertension","volume":"44","author":"New","year":"1977","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.bcp.2017.01.010_b0025","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/ng0895-394","article-title":"Human hypertension caused by mutations in the kidney isozyme of 11\u03b2-hydroxysteroid dehydrogenase","volume":"10","author":"Mune","year":"1995","journal-title":"Nat. Genet."},{"issue":"7","key":"10.1016\/j.bcp.2017.01.010_b0030","first-page":"2244","article-title":"Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess","volume":"83","author":"Dave-Sharma","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6 Pt 1","key":"10.1016\/j.bcp.2017.01.010_b0035","article-title":"Central hypertensinogenic effects of glycyrrhizic acid and carbenoxolone","volume":"263","author":"Gomez-Sanchez","year":"1992","journal-title":"Am. J. Physiol."},{"issue":"5","key":"10.1016\/j.bcp.2017.01.010_b0040","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1203\/00006450-197305000-00004","article-title":"The metabolic clearance rate, blood production, interconversion and transplacental passage of cortisol and cortisone in pregnancy near term","volume":"7","author":"Beitins","year":"1973","journal-title":"Pediatr. Res."},{"issue":"9129","key":"10.1016\/j.bcp.2017.01.010_b0045","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0140-6736(05)60824-0","article-title":"Fetal exposure to maternal cortisol","volume":"352","author":"Gitau","year":"1998","journal-title":"Lancet"},{"issue":"Pt 3","key":"10.1016\/j.bcp.2017.01.010_b0050","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1042\/bj3131007","article-title":"Cloning and production of antisera to human placental 11\u03b2-hydroxysteroid dehydrogenase type 2","volume":"313","author":"Brown","year":"1996","journal-title":"Biochem. J."},{"issue":"2","key":"10.1016\/j.bcp.2017.01.010_b0055","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1046\/j.1365-2265.1997.1230939.x","article-title":"Placental 11\u03b2-hydroxysteroid dehydrogenase: a key regulator of fetal glucocorticoid exposure","volume":"46","author":"Benediktsson","year":"1997","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"5","key":"10.1016\/j.bcp.2017.01.010_b0060","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1210\/jc.2010-2395","article-title":"A longitudinal study of plasma and urinary cortisol in pregnancy and postpartum","volume":"96","author":"Jung","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.bcp.2017.01.010_b0065","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.yhbeh.2010.06.007","article-title":"Glucocorticoids, prenatal stress and the programming of disease","volume":"59","author":"Harris","year":"2011","journal-title":"Horm. Behav."},{"issue":"2","key":"10.1016\/j.bcp.2017.01.010_b0070","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/apha.12187","article-title":"Foetal and placental 11\u03b2-HSD2: a hub for developmental programming","volume":"210","author":"Cottrell","year":"2014","journal-title":"Acta Physiol. (Oxf)"},{"issue":"Suppl. 6","key":"10.1016\/j.bcp.2017.01.010_b0075","doi-asserted-by":"crossref","first-page":"588S","DOI":"10.1080\/07315724.2004.10719428","article-title":"The developmental origins of adult disease","volume":"23","author":"Barker","year":"2004","journal-title":"J. Am. Coll. Nutr."},{"issue":"3","key":"10.1016\/j.bcp.2017.01.010_b0080","first-page":"757","article-title":"Elevated plasma cortisol concentrations: a link between low birth weight and the insulin resistance syndrome?","volume":"83","author":"Phillips","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1 Pt 1","key":"10.1016\/j.bcp.2017.01.010_b0085","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0002-9378(99)70160-2","article-title":"Repeated antenatal corticosteroids: size at birth and subsequent development","volume":"180","author":"French","year":"1999","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"Suppl. 3","key":"10.1016\/j.bcp.2017.01.010_b0090","doi-asserted-by":"crossref","first-page":"U49","DOI":"10.1530\/eje.0.151u049","article-title":"Prenatal glucocorticoids and long-term programming","volume":"151","author":"Seckl","year":"2004","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"10.1016\/j.bcp.2017.01.010_b0095","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/humrep\/13.4.799","article-title":"11\u03b2-Hydroxysteroid dehydrogenase type 2 in human pregnancy and reduced expression in intrauterine growth restriction","volume":"13","author":"Shams","year":"1998","journal-title":"Hum. Reprod."},{"issue":"8841","key":"10.1016\/j.bcp.2017.01.010_b0100","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0140-6736(93)90138-7","article-title":"Glucocorticoid exposure in utero: new model for adult hypertension","volume":"341","author":"Benediktsson","year":"1993","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bcp.2017.01.010_b0105","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.placenta.2007.10.010","article-title":"Placental 11\u03b2-hydroxysteroid dehydrogenase type 2 is reduced in pregnancies complicated with idiopathic intrauterine growth restriction: evidence that this is associated with an attenuated ratio of cortisone to cortisol in the umbilical artery","volume":"29","author":"Dy","year":"2008","journal-title":"Placenta"},{"issue":"10","key":"10.1016\/j.bcp.2017.01.010_b0110","first-page":"4979","article-title":"Reduced placental 11\u03b2-hydroxysteroid dehydrogenase type 2 mRNA levels in human pregnancies complicated by intrauterine growth restriction: an analysis of possible mechanisms","volume":"86","author":"McTernan","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.bcp.2017.01.010_b0115","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-2265.1995.tb02676.x","article-title":"Fetal osteocalcin levels are related to placental 11\u03b2-hydroxysteroid dehydrogenase activity in humans","volume":"42","author":"Benediktsson","year":"1995","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"1\u20132","key":"10.1016\/j.bcp.2017.01.010_b0120","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mce.2003.11.027","article-title":"The 11-ketosteroid 11-ketodexamethasone is a glucocorticoid receptor agonist","volume":"214","author":"Rebuffat","year":"2004","journal-title":"Mol. Cell. Endocrinol."},{"issue":"1","key":"10.1016\/j.bcp.2017.01.010_b0125","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0306-4522(01)00065-3","article-title":"Prenatal glucocorticoid programming of brain corticosteroid receptors and corticotrophin-releasing hormone: possible implications for behaviour","volume":"104","author":"Welberg","year":"2001","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/j.bcp.2017.01.010_b0130","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1046\/j.1460-9568.2000.00958.x","article-title":"Inhibition of 11\u03b2-hydroxysteroid dehydrogenase, the foeto-placental barrier to maternal glucocorticoids, permanently programs amygdala GR mRNA expression and anxiety-like behaviour in the offspring","volume":"12","author":"Welberg","year":"2000","journal-title":"Eur. J. Neurosci."},{"issue":"6","key":"10.1016\/j.bcp.2017.01.010_b0135","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1161\/01.HYP.27.6.1200","article-title":"Inhibition of 11\u03b2-hydroxysteroid dehydrogenase in pregnant rats and the programming of blood pressure in the offspring","volume":"27","author":"Lindsay","year":"1996","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.bcp.2017.01.010_b0140","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1210\/en.2008-1100","article-title":"Altered placental function of 11\u03b2-hydroxysteroid dehydrogenase 2 knockout mice","volume":"150","author":"Wyrwoll","year":"2009","journal-title":"Endocrinology"},{"issue":"6","key":"10.1016\/j.bcp.2017.01.010_b0145","doi-asserted-by":"crossref","first-page":"E1526","DOI":"10.1152\/ajpendo.00574.2006","article-title":"Maternal stress alters endocrine function of the feto-placental unit in rats","volume":"292","author":"Mairesse","year":"2007","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"2\u20133","key":"10.1016\/j.bcp.2017.01.010_b0150","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0143-4004(96)80010-5","article-title":"Protein intake in pregnancy, placental glucocorticoid metabolism and the programming of hypertension in the rat","volume":"17","author":"Langley-Evans","year":"1996","journal-title":"Placenta"},{"issue":"Suppl. 1","key":"10.1016\/j.bcp.2017.01.010_b0155","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.psyneuen.2007.03.014","article-title":"HPA axis programming by maternal undernutrition in the male rat offspring","volume":"32","author":"Vieau","year":"2007","journal-title":"Psychoneuroendocrinology"},{"issue":"6","key":"10.1016\/j.bcp.2017.01.010_b0160","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/ncpendmet0515","article-title":"Mechanisms of disease: glucocorticoids, their placental metabolism and fetal 'programming' of adult pathophysiology","volume":"3","author":"Seckl","year":"2007","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"issue":"10","key":"10.1016\/j.bcp.2017.01.010_b0165","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.bcp.2008.07.019","article-title":"Glucocorticoid and mineralocorticoid action: why should we consider influences by environmental chemicals?","volume":"76","author":"Odermatt","year":"2008","journal-title":"Biochem. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2017.01.010_b0170","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/aje\/kwf130","article-title":"Preterm birth and licorice consumption during pregnancy","volume":"156","author":"Strandberg","year":"2002","journal-title":"Am. J. Epidemiol."},{"issue":"10","key":"10.1016\/j.bcp.2017.01.010_b0175","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.psyneuen.2010.04.010","article-title":"Maternal prenatal licorice consumption alters hypothalamic-pituitary-adrenocortical axis function in children","volume":"35","author":"Raikkonen","year":"2010","journal-title":"Psychoneuroendocrinology"},{"issue":"9","key":"10.1016\/j.bcp.2017.01.010_b0180","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/aje\/kwp272","article-title":"Maternal licorice consumption and detrimental cognitive and psychiatric outcomes in children","volume":"170","author":"Raikkonen","year":"2009","journal-title":"Am. J. Epidemiol."},{"issue":"3","key":"10.1016\/j.bcp.2017.01.010_b0185","first-page":"1313","article-title":"Decreased gene expression of 11\u03b2-hydroxysteroid dehydrogenase type 2 and 15-hydroxyprostaglandin dehydrogenase in human placenta of patients with preeclampsia","volume":"86","author":"Schoof","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.bcp.2017.01.010_b0190","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1203\/PDR.0b013e31818d6c24","article-title":"Prematurity is related to high placental cortisol in preeclampsia","volume":"65","author":"Aufdenblatten","year":"2009","journal-title":"Pediatr. Res."},{"issue":"1","key":"10.1016\/j.bcp.2017.01.010_b0195","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/minf.201300063","article-title":"Pharmacophore model refinement for 11\u03b2-hydroxysteroid dehydrogenase inhibitors: search for modulators of intracellular glucocorticoid concentrations","volume":"33","author":"Vuorinen","year":"2014","journal-title":"Mol. Inform."},{"issue":"12","key":"10.1016\/j.bcp.2017.01.010_b0200","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1021\/jm0600794","article-title":"The discovery of new 11\u03b2-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening","volume":"49","author":"Schuster","year":"2006","journal-title":"J. Med. Chem."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2017.01.010_b0205","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jsbmb.2010.12.019","article-title":"Characterization of activity and binding mode of glycyrrhetinic acid derivatives inhibiting 11\u03b2-hydroxysteroid dehydrogenase type 2","volume":"125","author":"Kratschmar","year":"2011","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"2","key":"10.1016\/j.bcp.2017.01.010_b0210","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0006-291X(03)01359-7","article-title":"Inhibition of 11\u03b2-hydroxysteroid dehydrogenase type 2 by dithiocarbamates","volume":"308","author":"Atanasov","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.bcp.2017.01.010_b0215","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/toxsci\/kfs022","article-title":"The anabolic androgenic steroid fluoxymesterone inhibits 11\u03b2-hydroxysteroid dehydrogenase 2-dependent glucocorticoid inactivation","volume":"126","author":"Furstenberger","year":"2012","journal-title":"Toxicol. Sci."},{"issue":"14","key":"10.1016\/j.bcp.2017.01.010_b0220","doi-asserted-by":"crossref","first-page":"5995","DOI":"10.1021\/jm5004914","article-title":"Ligand-based pharmacophore modeling and virtual screening for the discovery of novel 17\u03b2-hydroxysteroid dehydrogenase 2 inhibitors","volume":"57","author":"Vuorinen","year":"2014","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2017.01.010_b0225","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/0003-2697(85)90442-7","article-title":"Measurement of protein using bicinchoninic acid","volume":"150","author":"Smith","year":"1985","journal-title":"Anal. Biochem."},{"issue":"3","key":"10.1016\/j.bcp.2017.01.010_b0230","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1006\/jmbi.1996.0897","article-title":"Development and validation of a genetic algorithm for flexible docking","volume":"267","author":"Jones","year":"1997","journal-title":"J. Mol. Biol."},{"issue":"17","key":"10.1016\/j.bcp.2017.01.010_b0235","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1021\/jm900639u","article-title":"Efficacious 11\u03b2-hydroxysteroid dehydrogenase type I inhibitors in the diet-induced obesity mouse model","volume":"52","author":"Wan","year":"2009","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2017.01.010_b0240","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.ejmech.2011.01.054","article-title":"Homology modeling and structural analysis of 11\u03b2-hydroxysteroid dehydrogenase type 2","volume":"46","author":"Yamaguchi","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2017.01.010_b0245","doi-asserted-by":"crossref","first-page":"287","DOI":"10.4137\/CIN.S8725","article-title":"Mouse 11\u03b2-hydroxysteroid dehydrogenase type 2 for human application: homology modeling, structural analysis and ligand-receptor interaction","volume":"10","author":"Yamaguchi","year":"2011","journal-title":"Cancer Inform."},{"issue":"1","key":"10.1016\/j.bcp.2017.01.010_b0250","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1021\/ci049885e","article-title":"LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters","volume":"45","author":"Wolber","year":"2005","journal-title":"J. Chem. Inf. Model."},{"issue":"9","key":"10.1016\/j.bcp.2017.01.010_b0255","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.bcp.2013.02.014","article-title":"Carbonyl reduction of triadimefon by human and rodent 11\u03b2-hydroxysteroid dehydrogenase 1","volume":"85","author":"Meyer","year":"2013","journal-title":"Biochem. Pharmacol."},{"issue":"12","key":"10.1016\/j.bcp.2017.01.010_b0260","doi-asserted-by":"crossref","first-page":"22799","DOI":"10.3390\/molecules201219880","article-title":"Pharmacophore models and pharmacophore-based virtual screening: concepts and applications exemplified on hydroxysteroid dehydrogenases","volume":"20","author":"Kaserer","year":"2015","journal-title":"Molecules"},{"issue":"11","key":"10.1016\/j.bcp.2017.01.010_b0265","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1289\/ehp.8209","article-title":"Organotins disrupt the 11\u03b2-hydroxysteroid dehydrogenase type 2-dependent local inactivation of glucocorticoids","volume":"113","author":"Atanasov","year":"2005","journal-title":"Environ. Health Perspect."},{"issue":"4","key":"10.1016\/j.bcp.2017.01.010_b0270","first-page":"1319","article-title":"Human 17\u03b2-hydroxysteroid dehydrogenase type 2 messenger ribonucleic acid expression and localization in term placenta and in endometrium during the menstrual cycle","volume":"83","author":"Mustonen","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"10.1016\/j.bcp.2017.01.010_b0275","first-page":"3710","article-title":"17\u03b2-hydroxysteroid dehydrogenase types 1 and 2 in human placenta: an immunohistochemical study with correlation to placental development","volume":"83","author":"Takeyama","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.bcp.2017.01.010_b0280","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1677\/jme.1.01736","article-title":"Comparative enzymology of 11\u03b2-hydroxysteroid dehydrogenase type 1 from six species","volume":"35","author":"Arampatzis","year":"2005","journal-title":"J. Mol. Endocrinol."},{"issue":"4","key":"10.1016\/j.bcp.2017.01.010_b0285","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1681\/ASN.2006111235","article-title":"Impaired protein stability of 11\u03b2-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess","volume":"18","author":"Atanasov","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"issue":"5 Pt 1","key":"10.1016\/j.bcp.2017.01.010_b0290","first-page":"E900","article-title":"Substrate and inhibitor specificity of the cloned human 11\u03b2-hydroxysteroid dehydrogenase type 2 isoform","volume":"270","author":"Ferrari","year":"1996","journal-title":"Am. J. Physiol."},{"issue":"4","key":"10.1016\/j.bcp.2017.01.010_b0295","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ddtec.2010.11.006","article-title":"3D pharmacophores as tools for activity profiling","volume":"7","author":"Schuster","year":"2010","journal-title":"Drug Discov. Today Technol."},{"issue":"10","key":"10.1016\/j.bcp.2017.01.010_b0300","doi-asserted-by":"crossref","first-page":"e46958","DOI":"10.1371\/journal.pone.0046958","article-title":"Virtual screening as a strategy for the identification of xenobiotics disrupting corticosteroid action","volume":"7","author":"Nashev","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.bcp.2017.01.010_b0305","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1530\/eje.0.1420200","article-title":"In the search for specific inhibitors of human 11\u03b2-hydroxysteroid-dehydrogenases (11\u03b2-HSDs): chenodeoxycholic acid selectively inhibits 11\u03b2-HSD-I","volume":"142","author":"Diederich","year":"2000","journal-title":"Eur. J. Endocrinol."},{"issue":"3","key":"10.1016\/j.bcp.2017.01.010_b0310","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2146\/ajhp070532","article-title":"Posaconazole: a new oral antifungal agent with an expanded spectrum of activity","volume":"66","author":"Morris","year":"2009","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"2","key":"10.1016\/j.bcp.2017.01.010_b0315","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1128\/AAC.40.2.279","article-title":"Antifungal agents: chemotherapeutic targets and immunologic strategies","volume":"40","author":"Georgopapadakou","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.bcp.2017.01.010_b0320","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1365-2710.2001.00338.x","article-title":"Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics","volume":"26","author":"Willems","year":"2001","journal-title":"J. Clin. Pharm. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2017.01.010_b0325","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1124\/dmd.32.2.267","article-title":"Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil)","volume":"32","author":"Ghosal","year":"2004","journal-title":"Drug Metab. Dispos."},{"issue":"10","key":"10.1016\/j.bcp.2017.01.010_b0330","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1124\/dmd.104.000315","article-title":"Role of itraconazole metabolites in CYP3A4 inhibition","volume":"32","author":"Isoherranen","year":"2004","journal-title":"Drug Metab. Dispos."},{"issue":"5","key":"10.1016\/j.bcp.2017.01.010_b0335","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ejps.2004.01.005","article-title":"Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study","volume":"21","author":"Wexler","year":"2004","journal-title":"Eur. J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.bcp.2017.01.010_b0340","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/clpt.2011.53","article-title":"Evaluation of 6\u03b2-hydroxycortisol, 6\u03b2-hydroxycortisone, and a combination of the two as endogenous probes for inhibition of CYP3A4 in vivo","volume":"89","author":"Peng","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.bcp.2017.01.010_b0345","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1124\/dmd.115.067744","article-title":"Evaluation of ketoconazole and its alternative clinical CYP3A4\/5 inhibitors as inhibitors of drug transporters: the in vitro effects of ketoconazole, ritonavir, clarithromycin, and itraconazole on 13 clinically-relevant drug transporters","volume":"44","author":"Vermeer","year":"2016","journal-title":"Drug Metab. Dispos."},{"issue":"12","key":"10.1016\/j.bcp.2017.01.010_b0350","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1592\/phco.26.12.1730","article-title":"Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants","volume":"26","author":"Saad","year":"2006","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.bcp.2017.01.010_b0355","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.reprotox.2006.01.007","article-title":"P-glycoprotein in the placenta: expression, localization, regulation and function","volume":"22","author":"Ceckova-Novotna","year":"2006","journal-title":"Reprod. Toxicol."},{"issue":"11","key":"10.1016\/j.bcp.2017.01.010_b0360","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1210\/en.2006-0633","article-title":"P-glycoprotein restricts access of cortisol and dexamethasone to the glucocorticoid receptor in placental BeWo cells","volume":"147","author":"Mark","year":"2006","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.bcp.2017.01.010_b0365","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ancard.2014.05.007","article-title":"Itraconazole: a new drug-related cause of hypertension","volume":"63","author":"Denolle","year":"2014","journal-title":"Ann. Cardiol. Angeiol. (Paris)"},{"issue":"4","key":"10.1016\/j.bcp.2017.01.010_b0370","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1128\/AAC.35.4.707","article-title":"High-dose itraconazole in the treatment of severe mycoses","volume":"35","author":"Sharkey","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2017.01.010_b0375","unstructured":"Janssen-Cilag-AG, Sporanox drug safety sheet, (2015)."},{"key":"10.1016\/j.bcp.2017.01.010_b0380","unstructured":"MSD-MERCK-SHARP&DOHME-AG, NOXAFIL Inf Konz 18mg\/ml drug safety sheet, (2014)."},{"issue":"9","key":"10.1016\/j.bcp.2017.01.010_b0385","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1128\/AAC.47.9.2788-2795.2003","article-title":"Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults","volume":"47","author":"Courtney","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.bcp.2017.01.010_b0390","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1128\/AAC.00663-08","article-title":"Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects","volume":"53","author":"Conte","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.bcp.2017.01.010_b0395","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2165\/00002018-200932030-00006","article-title":"First-trimester itraconazole exposure and pregnancy outcome: a prospective cohort study of women contacting teratology information services in Italy","volume":"32","author":"De Santis","year":"2009","journal-title":"Drug Saf."},{"issue":"9191","key":"10.1016\/j.bcp.2017.01.010_b0400","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0140-6736(99)04411-6","article-title":"Reporting bias in retrospective ascertainment of drug-induced embryopathy","volume":"354","author":"Bar-Oz","year":"1999","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.bcp.2017.01.010_b0405","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1067\/mob.2000.105962","article-title":"Pregnancy outcome after in utero exposure to itraconazole: a prospective cohort study","volume":"183","author":"Bar-Oz","year":"2000","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"9656","key":"10.1016\/j.bcp.2017.01.010_b0410","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/S0140-6736(08)61929-7","article-title":"Multiple courses of antenatal corticosteroids for preterm birth (MACS): a randomised controlled trial","volume":"372","author":"Murphy","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.bcp.2017.01.010_b0415","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ajog.2006.03.087","article-title":"Single versus weekly courses of antenatal corticosteroids: evaluation of safety and efficacy","volume":"195","author":"Wapner","year":"2006","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"4","key":"10.1016\/j.bcp.2017.01.010_b0420","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3109\/14767050903165222","article-title":"Review and meta-analysis: benefits and risks of multiple courses of antenatal corticosteroids","volume":"23","author":"Bevilacqua","year":"2010","journal-title":"J. Matern. Fetal Neonatal"},{"issue":"10","key":"10.1016\/j.bcp.2017.01.010_b0425","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1172\/JCI1567","article-title":"Glucocorticoid exposure in late gestation permanently programs rat hepatic phosphoenolpyruvate carboxykinase and glucocorticoid receptor expression and causes glucose intolerance in adult offspring","volume":"101","author":"Nyirenda","year":"1998","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.bcp.2017.01.010_b0430","first-page":"267","article-title":"Hedgehog signaling has a protective effect in glucocorticoid-induced mouse neonatal brain injury through an 11\u03b2-HSD2-dependent mechanism","volume":"119","author":"Heine","year":"2009","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.bcp.2017.01.010_b0435","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ccr.2010.02.027","article-title":"Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth","volume":"17","author":"Kim","year":"2010","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.bcp.2017.01.010_b0440","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1021\/acs.jmedchem.5b01718","article-title":"Repurposing the clinically efficacious antifungal agent itraconazole as an anticancer chemotherapeutic","volume":"59","author":"Pace","year":"2016","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2017.01.010_b0445","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1158\/1535-7163.MCT-15-0729-T","article-title":"Posaconazole, a second-generation triazole antifungal drug, inhibits the hedgehog signaling pathway and progression of basal cell carcinoma","volume":"15","author":"Chen","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.bcp.2017.01.010_b0450","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1021\/cb600362d","article-title":"Inhibition of angiogenesis by the antifungal drug itraconazole","volume":"2","author":"Chong","year":"2007","journal-title":"ACS Chem. Biol."},{"issue":"4","key":"10.1016\/j.bcp.2017.01.010_b0455","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.biopha.2011.11.004","article-title":"Itraconazole inhibits HMEC-1 angiogenesis","volume":"66","author":"Del Carratore","year":"2012","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.bcp.2017.01.010_b0460","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1055\/s-0030-1253453","article-title":"Placental vasculature in health and disease","volume":"36","author":"Khankin","year":"2010","journal-title":"Semin. Thromb. Hemost."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295217300400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295217300400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:00:01Z","timestamp":1757768401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295217300400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":92,"alternative-id":["S0006295217300400"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2017.01.010","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of 11\u03b2-hydroxysteroid dehydrogenase 2 by the fungicides itraconazole and posaconazole","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2017.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}